Court Place Advisors LLC Sells 12,185 Shares of Pfizer Inc. (NYSE:PFE)

Court Place Advisors LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 20.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 48,257 shares of the biopharmaceutical company’s stock after selling 12,185 shares during the period. Court Place Advisors LLC’s holdings in Pfizer were worth $1,389,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Worth Asset Management LLC bought a new position in shares of Pfizer during the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc purchased a new stake in Pfizer in the 3rd quarter worth $30,000. Sanctuary Wealth Management L.L.C. acquired a new position in shares of Pfizer during the fourth quarter valued at approximately $50,000. Mizuho Securities Co. Ltd. purchased a new position in shares of Pfizer in the third quarter worth about $34,000. Finally, VisionPoint Advisory Group LLC increased its position in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE stock traded down $0.29 during trading on Wednesday, hitting $25.41. The company had a trading volume of 43,790,104 shares, compared to its average volume of 42,573,164. Pfizer Inc. has a 1-year low of $25.26 and a 1-year high of $41.33. The firm has a 50-day moving average price of $27.23 and a 200-day moving average price of $28.79. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market cap of $143.86 billion, a PE ratio of 71.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 EPS. On average, analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.